<DOC>
	<DOC>NCT01826045</DOC>
	<brief_summary>The purpose of this study is to determine the efficacy and the safety of PGA(Poly-gamma Glutamic Acid) for the the fertile women with Cervical Intraepithelial Neoplasia (CIN1).</brief_summary>
	<brief_title>Efficacy and Safety Study of PGA (Poly-gamma Glutamic Acid) for Cervical Intraepithelial Neoplasia</brief_title>
	<detailed_description>This study is to compare the regression rate of Cervical Intraepithelial Neoplasia (CIN1) between the treatment group and the control group. The treatment group will be administered with PGA (Poly-gamma Glutamic Acid) for 4 weeks followed by 8 weeks observation. The control group will be observed for 12 weeks without any comparator.</detailed_description>
	<mesh_term>Neoplasms</mesh_term>
	<mesh_term>Carcinoma in Situ</mesh_term>
	<mesh_term>Cervical Intraepithelial Neoplasia</mesh_term>
	<criteria>Fertile women between age of 20 and 49 Patients with cervical intraepithelial neoplasia 1(CIN1) HPV(Human Papilloma Virus) positive(+) White Blood Cell Count(WBC) over 4thous/ul, Hemoglobin above over 9.0g/dL Platelet over 150thous/uL and ANC(Absolute Neutrophil Count) over 1,500 10^6/L AST(Aspartate Aminotransferase) no less than 4 times higher than normal ALT(Alanine Aminotransferase) no less than 4 times higher than normal Normal for EKG(Electrocardiography) and no active disease detected trough chest Xray Be informed of the nature of the study and will give written informed consent Malignant tumor in any organ other than cervical intraepithelial neoplasia Active liver disease, immune disorder and severe renal failure Leukemia, collagenosis, sclerosis, autoimmune disease, clinically significant allergic disease(mild allergic symptom not required medicine excluded) Diagnosed diabetes Taking any of followings affecting immunological reaction within 7 days (Glucocorticoid, vitamins, health food and oriental medicine etc) Pregnancy and breastfeeding Registered in other clinical trials Patients whom the investigator considers inappropriate to participate in the study</criteria>
	<gender>Female</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>49 Years</maximum_age>
	<verification_date>January 2016</verification_date>
	<keyword>Treatment of Cervical Intraepithelial Neoplasia(CIN1)</keyword>
</DOC>